Alpha Tau Medical
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 121
- Market Cap
- -
- Website
- http://www.alphatau.com
- Introduction
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.
Clinical Trials
28
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
- Conditions
- Recurrent GlioblastomaRecurrent Gliomas
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Alpha Tau Medical LTD.
- Target Recruit Count
- 10
- Registration Number
- NCT06910306
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer
- Conditions
- Pancreatic CancerLocally Advanced Pancreatic Cancer
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Alpha Tau Medical LTD.
- Target Recruit Count
- 40
- Registration Number
- NCT06755359
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷Centre Jean PERRIN - Clermont-Ferrand, Clermont-Ferrand, France
🇫🇷Centre Georges François Leclerc Dijon, Dijon, France
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
- Conditions
- Pancreatic CancerPancreatic AdenocarcinomaMetastatic Pancreatic Cancer
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Alpha Tau Medical LTD.
- Target Recruit Count
- 30
- Registration Number
- NCT06698458
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Goodyear, Arizona, United States
🇺🇸Honor Health, Scottsdale, Arizona, United States
Clinical Study Protocol for Cutaneous SCC for Immunocompromised Patients
- Conditions
- Squamous Cell CarcinomaAlpha RadiationImmunocompromisedCarcinoma, SquamousSkin CancerBrachytherapy
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Alpha Tau Medical LTD.
- Target Recruit Count
- 28
- Registration Number
- NCT06615635
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.
- Conditions
- Recurrent Breast CancerBreast CancerBreast Carcinoma
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Alpha Tau Medical LTD.
- Target Recruit Count
- 10
- Registration Number
- NCT06202118
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Oramed Pharmaceuticals Invests $36.9 Million in Alpha Tau Medical to Advance Cancer Radiation Therapy
Oramed Pharmaceuticals has invested $36.9 million in Alpha Tau Medical, acquiring approximately 14.1 million shares and establishing a three-year strategic collaboration to accelerate Alpha DaRT cancer therapy development.
Alpha Tau Secures MDSAP Certification for Alpha DaRT Cancer Therapy Manufacturing Facility
Alpha Tau Medical has achieved MDSAP certification for its Jerusalem manufacturing facility, marking a significant milestone in quality and regulatory compliance for its alpha-radiation cancer therapy technology.
Alpha Tau Medical's Alpha DaRT Receives FDA Advisory Program Acceptance and Advances Clinical Trials
Alpha Tau Medical's Alpha DaRT therapy has been accepted into the FDA's Total Product Life Cycle Advisory Program for recurrent glioblastoma multiforme (GBM).
Alpha Tau Medical's Alpha DaRT Receives FDA Support and Advances in Clinical Trials
Alpha Tau Medical's Alpha DaRT therapy gains FDA acceptance into the Total Product Life Cycle Advisory Program for recurrent glioblastoma multiforme, aiming to expedite market access.